Publications by authors named "X Dhalluin"

Claim this Profile
D
Durvalumab in Patients With Treatment-Naive Stage IV NSCLC With an ECOG Performance Status of 2 to 3 and High PD-L1 Tumor Expression (IFCT-1802 SAVIMMUNE): A Multicenter Phase 2 Trial.
Valérie Gounant, Laurent Greillier, Céline Mascaux, François Pinquie, Delphine Carmier, Xavier Dhalluin

JTO Clin Res Rep· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[The impact of bronchoalveolar lavage in patients intubated for COVID-19].
L A Pernaut, F Wallyn, X Dhalluin, O Ouennoure, A Rouzé

Rev Mal Respir· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Salvage Immunotherapy With Pembrolizumab in Patients Hospitalized for Life-Threatening Complications of NSCLC.
Ferréol Roborel de Climens, Christos Chouaid, Claire Poulet, Vincent Leroy, Luc Stoven, Xavier Dhalluin

JTO Clin Res Rep· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antiplatelet Drugs and Risk of Bleeding After Bedside Pleural Procedures: A National Multicenter Cohort Study.
Laurence Dangers, Jonathan Giovannelli, Gilles Mangiapan, Mikael Alves, Naïke Bigé, Xavier Dhalluin

Chest· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Does Very Poor Performance Status Systematically Preclude Single Agent Anti-PD-1 Immunotherapy? A Multicenter Study of 35 Consecutive Patients.
Valérie Gounant, Michael Duruisseaux, Ghassen Soussi, Sylvie Van Hulst, Olivier Bylicki, Xavier Dhalluin

Cancers (Basel)· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis